MX2022012488A - Formulaciones farmaceuticas. - Google Patents
Formulaciones farmaceuticas.Info
- Publication number
- MX2022012488A MX2022012488A MX2022012488A MX2022012488A MX2022012488A MX 2022012488 A MX2022012488 A MX 2022012488A MX 2022012488 A MX2022012488 A MX 2022012488A MX 2022012488 A MX2022012488 A MX 2022012488A MX 2022012488 A MX2022012488 A MX 2022012488A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- chelating group
- composition
- radiohybrid
- fluoride
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000007979 citrate buffer Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- ABTOQLMXBSRXSM-UHFFFAOYSA-N silicon tetrafluoride Chemical compound F[Si](F)(F)F ABTOQLMXBSRXSM-UHFFFAOYSA-N 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende un agente radiohíbrido que contiene un fluoruro de silicio y un grupo quelante en donde el flúor es 18F o el grupo quelante contiene un metal radiactivo quelado, en donde la composición tiene un pH de 4.0-6.0 y además comprende: amortiguador de citrato 0.1-200 mM; 1-100 mg/ml de etanol; y 5-10 mg/mL de cloruro de sodio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005282.5A GB202005282D0 (en) | 2020-04-09 | 2020-04-09 | Pharmaceutical Formulations |
| PCT/GB2021/050877 WO2021205185A1 (en) | 2020-04-09 | 2021-04-09 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012488A true MX2022012488A (es) | 2023-01-16 |
Family
ID=70848115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012488A MX2022012488A (es) | 2020-04-09 | 2021-04-09 | Formulaciones farmaceuticas. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12036290B2 (es) |
| EP (1) | EP4132592A1 (es) |
| JP (1) | JP2023521402A (es) |
| KR (1) | KR20230024258A (es) |
| CN (1) | CN115484992A (es) |
| AU (1) | AU2021252191B2 (es) |
| BR (1) | BR112022020359A2 (es) |
| CA (1) | CA3179555A1 (es) |
| GB (1) | GB202005282D0 (es) |
| IL (1) | IL297067A (es) |
| MX (1) | MX2022012488A (es) |
| WO (1) | WO2021205185A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005282D0 (en) | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001346A1 (en) | 1993-06-30 | 1995-01-12 | Akzo Nobel N.V. | Chelating compounds |
| JP2005519861A (ja) | 2001-07-27 | 2005-07-07 | ターゲサム・インコーポレーテッド | 治療剤及び撮像剤としての脂質構築物 |
| EP1356827A1 (en) * | 2002-04-24 | 2003-10-29 | Mallinckrodt Inc. | Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution |
| ES2347535T3 (es) | 2002-11-05 | 2010-11-02 | Ion Beam Applications S.A. | Estabilizacion de composiciones acuosas de 2-fluoro-2-desoxi-d-glucosa marcada con el isotopo 18f con etanol. |
| ES2621950T3 (es) * | 2010-12-29 | 2017-07-05 | Ge Healthcare Limited | Disolución de eluyente |
| EP2793954B1 (en) * | 2011-12-21 | 2020-10-21 | GE Healthcare Limited | 18f-fluciclovine compositions in citrate buffers |
| CN102626522B (zh) | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| GB201402132D0 (en) | 2014-02-07 | 2014-03-26 | South African Nuclear Energy | A method of producing ethylenedicysteine deoxyglucosamine (ECDG) or a salt thereof and its application in a kit |
| RU2743781C2 (ru) | 2014-06-10 | 2021-02-25 | 3Б Фармасьютикалз Гмбх | Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение |
| WO2016062370A1 (en) | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| SG11202000725WA (en) * | 2017-07-28 | 2020-02-27 | Univ Muenchen Tech | Dual mode radiotracer and -therapeutics |
| CN111712265B (zh) * | 2018-01-24 | 2024-02-09 | Ac免疫有限公司 | 用于pet显像的诊断组合物、该诊断组合物的制备方法及其在诊断中的用途 |
| EP3636635A1 (en) | 2018-10-11 | 2020-04-15 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Imaging agents |
| WO2020157177A1 (en) | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| JP7421232B2 (ja) | 2019-01-30 | 2024-01-24 | テクニシェ ユニバーシタット ミュンヘン | フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体 |
| CN116585494A (zh) | 2019-01-30 | 2023-08-15 | 慕尼黑工业大学 | 癌症诊断成像剂 |
| US20230106083A1 (en) | 2019-04-26 | 2023-04-06 | The Regents Of The University Of California | Silicon-fluoride heteroaromatic systems for applications in positron emission tomography (pet) molecular imaging |
| EP3986872A4 (en) | 2019-06-21 | 2024-02-21 | Provincial Health Services Authority | RADIOM LABELED COMPOUNDS DIRECTED AGAINST THE PROSTATE SPECIFIC MEMBRANE ANTIGEN |
| GB202005282D0 (en) | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| EP4023250A1 (en) | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| EP4291250A1 (en) | 2021-02-15 | 2023-12-20 | Technische Universität München | Dual mode radiotracer and therapeutics |
| EP4043041A1 (en) | 2021-02-15 | 2022-08-17 | Technische Universität München | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
-
2020
- 2020-04-09 GB GBGB2005282.5A patent/GB202005282D0/en not_active Ceased
-
2021
- 2021-04-09 US US17/226,848 patent/US12036290B2/en active Active
- 2021-04-09 WO PCT/GB2021/050877 patent/WO2021205185A1/en unknown
- 2021-04-09 AU AU2021252191A patent/AU2021252191B2/en active Active
- 2021-04-09 KR KR1020227038676A patent/KR20230024258A/ko active Search and Examination
- 2021-04-09 EP EP21719231.9A patent/EP4132592A1/en active Pending
- 2021-04-09 BR BR112022020359A patent/BR112022020359A2/pt unknown
- 2021-04-09 CA CA3179555A patent/CA3179555A1/en active Pending
- 2021-04-09 MX MX2022012488A patent/MX2022012488A/es unknown
- 2021-04-09 CN CN202180032103.4A patent/CN115484992A/zh active Pending
- 2021-04-09 IL IL297067A patent/IL297067A/en unknown
- 2021-04-09 JP JP2022562020A patent/JP2023521402A/ja active Pending
-
2024
- 2024-02-07 US US18/435,245 patent/US20240277875A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12036290B2 (en) | 2024-07-16 |
| CA3179555A1 (en) | 2021-10-14 |
| AU2021252191A1 (en) | 2022-10-27 |
| CN115484992A (zh) | 2022-12-16 |
| WO2021205185A1 (en) | 2021-10-14 |
| AU2021252191B2 (en) | 2024-05-02 |
| US20210322581A1 (en) | 2021-10-21 |
| EP4132592A1 (en) | 2023-02-15 |
| JP2023521402A (ja) | 2023-05-24 |
| GB202005282D0 (en) | 2020-05-27 |
| IL297067A (en) | 2022-12-01 |
| US20240277875A1 (en) | 2024-08-22 |
| BR112022020359A2 (pt) | 2022-12-13 |
| KR20230024258A (ko) | 2023-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW340045B (en) | Extended zero order release pharmaceutical composition | |
| TW200716144A (en) | Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis | |
| HUP9701690A2 (hu) | Gombaellenes hatású tetrahidrofuránszármazékok és az ezeket tartalmazó gyógyszerkészítmények | |
| ES2190075T3 (es) | Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico. | |
| CO4700482A1 (es) | Formulaciones de un analogo monomero de insulina | |
| MX173189B (es) | Mejoras a composicion oral anticalculo | |
| HUP9802086A2 (hu) | Piperidino-alkanol vegyületeket tartalmazó gyógyszerkészítmények | |
| BR0316532A (pt) | Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base | |
| MX2022012488A (es) | Formulaciones farmaceuticas. | |
| NZ508222A (en) | Cysteine derivatives and their use as nitric oxide synthase inhibitors | |
| PE20020853A1 (es) | Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas | |
| KR890015738A (ko) | 이포스폰산 유도체를 기제로 하는, 경구 투역용 약학적 조성물 | |
| ES2195344T3 (es) | Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico. | |
| GR3027634T3 (en) | Gallium (iii) complexes, process for their obtention and pharmaceutical compositions containing them. | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| IL140848A (en) | Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate | |
| HUP0103431A2 (hu) | 5-HT4 receptor agonista vagy antagonista hatóanyagot tartalmazó, orális gyógyászati készítmény | |
| HUP0204202A2 (hu) | Ibuprofent tartalmazó hatóanyag-preparátum, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények | |
| PH12020552098A1 (en) | Solid preparation composition for oral application of colonic purgative containing anhydrous sodium sulfate, potassium sulfate, anhydrous magnesium sulfate, and simethicone | |
| US6114387A (en) | Pharmaceutical composition for oral administration of chelating agents | |
| MXPA03001060A (es) | Composiciones para mejorar el trastorno de hiperactividad con deficit de atencion. | |
| PE20011113A1 (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina | |
| EP1080728A1 (en) | Prostaglandin ep4 receptor agonist and treatment method | |
| GB2282758A (en) | Oral morphine-6-glucuronide compositions | |
| GB2407504A (en) | Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections |